乳腺癌中HR、HER2和Ki-67联合检测在不同分子亚型中的预后预测价值分析OA
Analysis of the prognostic predictive value of combined detection of HR,HER2,and Ki-67 in different molecular subtypes of breast cancer
目的:评估激素受体(HR)、人类表皮生长因子受体2(HER2)与 Ki-67增殖指数联合检测在不同分子亚型乳腺癌中的预后预测价值.方法:回顾性纳入2020 年 1 月至2025 年 6月就诊的 120 例乳腺癌患者,按分子亚型分为 Luminal A 型、Luminal B 型、HER2过表达型和三阴性四组,每组 30 例.分析各分子标志物在不同亚型中的表达差异及其与预后的关系,并利用受试者工作特征曲线(ROC)评估联合检测的诊断效能.结果:各分子亚型间HR、HER2与Ki-67表达存在差异(P<0.05).生存分析显示不同亚型患者预后不同(P<0.05),Luminal A型最佳,三阴性型最差.Cox多因素分析证实HER2阳性、Ki-67高表达、HR阳性是影响无疾病生存期的独立危险因素.ROC曲线分析进一步表明,三项标志物联合检测的预测效能优于任一单一指标(P<0.05).结论:HR、HER2与Ki-67联合检测对乳腺癌分子亚型预后有预测价值,尤其适用于高危亚型,可提升复发与生存预测准确性,指导个体化治疗.
Objective:To evaluate the prognostic value of combined detection of hormone receptor(HR),human epidermal growth factor receptor 2(HER2),and Ki-67 proliferation index in different molecular subtypes of breast cancer.Methods:A total of 120 breast cancer patients treated from January 2020 to June 2025 were retrospectively included and divided into four groups according to molecular subtypes:Luminal A,Luminal B,HER2-overexpressing,and triple-negative,with 30 cases in each group.The expression differences of molecular markers across subtypes and their associations with prognosis were analyzed.The diagnostic efficacy of combined detection was as-sessed using receiver operating characteristic(ROC)curves.Results:Significant differences in the expression of HR,HER2,and Ki-67 were observed among molecular subtypes(P<0.05).Survival analysis revealed significantly different prognoses across subtypes(P<0.05),with the Luminal A subtype showing the best and the triple-negative subtype the worst outcomes.Multivariate Cox regression analysis confirmed that HER2 positivity,high Ki-67 expression and HR positivity were independent risk factors for disease-free survival.ROC curve analysis further demonstrated that the combined detection of the three markers was significantly superior to any single indicator(P<0.05).Conclusions:The combined detection of HR,HER2,and Ki-67 demonstrated significant prognostic value in different molecular subtypes of breast cancer,partic-ularly in high-risk subtypes,and may enhance the accuracy of recurrence and survival prediction,thereby guiding individualized treatment.
刘俊林;郑杰;姚佳;吴双
荆门市中心医院,湖北 荆门 448124荆门市中心医院,湖北 荆门 448124荆门市中心医院,湖北 荆门 448124荆门市中心医院,湖北 荆门 448124
医药卫生
乳腺癌分子亚型激素受体人类表皮生长因子受体2Ki-67增殖指数联合检测
breast cancermolecular subtypehormone receptorhuman epidermal growth factor receptor 2ki-67 proliferation in-dexcombined detection
《甘肃医药》 2026 (7)
600-603,4
荆门市科学技术研究与开发计划引导项目(编号:2025YDKY076)
评论